Cumberland Pharmaceuticals Inc. Business Combination, Contingent Consideration, Liability
Cumberland Pharmaceuticals Inc. (CPIX) had Business Combination, Contingent Consideration, Liability of $1.00 million as of 2021-10-31, per its 10-K filed 2023-03-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2023-03-13
- 2021-10-31: Business Combination, Contingent Consideration, Liability $1.00M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2021-10-31 | $1.00M 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |